Posted by Michael Wonder on 23 Jan 2023
Brukinsa (zanubrutinib) receives marketing authorisation for chronic lymphocytic leukaemia and marginal zone lymphoma in Great Britain by MHRA
19 January 2023 - Brukinsa is the only treatment authorised for marginal zone lymphoma in Great Britain
BeiGene today announced that the MHRA has granted marketing authorizations for Brukinsa (zanubrutinib) in Great Britain for both the treatment of adult patients with chronic lymphocytic leukaemia and the treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20 based therapy.
